Posted by: admin on: December 6, 2011
The new calcium channel blocker azelnidipine found to have an added effect on Olmesartan action on hypertensive diabetic patients, has an advantage in chronic kidney patients. Here is the study. Team@CMHF
Enter your email address:
This Widget requires Javascript
Height in cm:
Weight in kg:
Your BMI is .
Check your Body Mass Index »